Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for infectious complications after gastrectomy in older patients.
Iida M, Takeda S, Yamamoto T, Nakashima C, Nishiyama M, Watanabe Y, Shindo Y, Tokumitsu Y, Tomochika S, Nakagami Y, Takahashi H, Nagano H. Iida M, et al. Among authors: nakagami y. Exp Ther Med. 2024 Jun 17;28(2):319. doi: 10.3892/etm.2024.12608. eCollection 2024 Aug. Exp Ther Med. 2024. PMID: 38939176 Free PMC article.
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Suzuki N, et al. Among authors: nakagami y. Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29. Int J Clin Oncol. 2019. PMID: 31144145 Free PMC article. Clinical Trial.
Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Kuwahara T, et al. Among authors: nakagami y. Br J Cancer. 2019 Oct;121(8):659-665. doi: 10.1038/s41416-019-0559-6. Epub 2019 Sep 6. Br J Cancer. 2019. PMID: 31488881 Free PMC article.
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials.
Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Maeda H, et al. Among authors: nakagami y. Oncol Lett. 2019 Nov;18(5):4555-4562. doi: 10.3892/ol.2019.10787. Epub 2019 Aug 29. Oncol Lett. 2019. PMID: 31611963 Free PMC article.
Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Kuwahara T, et al. Among authors: nakagami y. Br J Cancer. 2019 Nov;121(11):983-984. doi: 10.1038/s41416-019-0605-4. Br J Cancer. 2019. PMID: 31624318 Free PMC article.
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. Nakajima M, et al. Among authors: nakagami y. Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. doi: 10.1007/s00262-020-02518-7. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219501 Free PMC article. Clinical Trial.
Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.
Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Nakashima-Nakasuga C, et al. Among authors: nakagami y. Int J Clin Oncol. 2020 Jul;25(7):1308-1317. doi: 10.1007/s10147-020-01673-2. Epub 2020 Apr 11. Int J Clin Oncol. 2020. PMID: 32277394
The effect of the visceral fat area on the predictive accuracy of C-reactive protein for infectious complications after laparoscopy-assisted gastrectomy.
Iida M, Takeda S, Nakagami Y, Kanekiyo S, Nakashima C, Nishiyama M, Yoshida S, Suzuki N, Yoshino S, Nagano H. Iida M, et al. Among authors: nakagami y. Ann Gastroenterol Surg. 2020 Mar 31;4(4):386-395. doi: 10.1002/ags3.12329. eCollection 2020 Jul. Ann Gastroenterol Surg. 2020. PMID: 32724882 Free PMC article.
Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer.
Yamada K, Hazama S, Suzuki N, Xu M, Nakagami Y, Fujiwara N, Tsunedomi R, Yoshida S, Tomochika S, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Watanabe Y, Iida M, Takeda S, Ioka T, Ueno T, Ogihara H, Hamamoto Y, Hoshii Y, Kawano H, Fujita T, Kawakami Y, Nagano H. Yamada K, et al. Among authors: nakagami y. Oncol Lett. 2021 Jan;21(1):10. doi: 10.3892/ol.2020.12271. Epub 2020 Nov 3. Oncol Lett. 2021. PMID: 33240416 Free PMC article.
206 results